Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye; Bohan Ma; Lei Li; Zixi Wang; Mingming Lu; Jialu Kang; Yuzeshi Lei; Shan Xu; Ke Wang; Yanlin Jian; Yizeng Fan; Bin Wang; Jing Liu; Yang Gao; Jian Ma; Lei Li

doi:10.1158/0008-5472.30125743

September 15, 2025Open Access

Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

View Full Paper

Ask AI

Bookmark

Share

Key Points

BRCA2 degradation increases sensitivity to PARP inhibition in metastatic castration-resistant prostate cancer.
The study uses a prostate cancer PDX model to support findings related to BRCA2 and PARP.
Immunofluorescent characterization highlights changes in cancer cell behavior post-treatment.
Findings suggest peptide-based PROTACs could be important for treating resistant prostate cancer.

Implication

Histological and immunofluorescent characterization reveals insights into prostate cancer PDX model, suggesting potential for improved PARP inhibition.

Abstract

Supplementary Fig. S6. Histological and immunofluorescent characterization of the prostate cancer PDX model. Related to Fig. 5.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fbc https://doi.org/10.1158/0008-5472.30125743

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading